American Journal of Cardiology
Volume 107, Issue 1 , Pages 24-29 , January 2011

Treatment and Outcomes of First Troponin-Negative Non–ST-Segment Elevation Myocardial Infarction

Received 7 May 2010 ,Revised 13 August 2010 ,Accepted 13 August 2010.

References 

  1. Jernberg T, Lindahl B. A combination of troponin T and 12-lead electrocardiography: a valuable tool for early prediction of long-term mortality in patients with chest pain without ST-segment elevation. Am Heart J. 2002;144:804–810
  2. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361:868–877
  3. Polanczyk CA, Lee TH, Cook EF, Walls R, Wybenga D, Printy-Klein G, et al. Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain. J Am Coll Cardiol. 1998;32:8–14
  4. Januzzi JL, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, et al. Predicting a late positive serum troponin in initially troponin-negative patients with non–ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J. 2006;151:360–366
  5. Newby LK, Christenson RH, Ohman EM, Armstrong PW, Thompson TD, Lee KL, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes (The GUSTO-IIa Investigators). Circulation. 1998;98:1853–1859
  6. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887
  7. Chase M, Robey JL, Zogby KE, Sease KL, Shofer FS, Hollander JE. Prospective validation of the Thrombolysis in Myocardial Infarction Risk Score in the emergency department chest pain population. Ann Emerg Med. 2006;48:252–259
  8. Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002;288:3124–3129
  9. Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J. 2007;153:29–35
  10. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non–ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286:2405–2412
  11. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718
  12. Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 2002;287:3087–3095
  13. Nissen SE. Pathobiology, not angiography, should guide management in acute coronary syndrome/non–ST-segment elevation myocardial infarction: the non-interventionist's perspective. J Am Coll Cardiol. 2003;41(suppl):103S–112S
  14. Missel E, Mintz GS, Carlier SG, Sano K, Qian J, Kaple RK, et al. Necrotic core and its ratio to dense calcium are predictors of high-risk non–ST-elevation acute coronary syndrome. Am J Cardiol. 2008;101:573–578
  15. Wu X, Maehara A, Mintz GS, Kubo T, Xu K, Choi SY, et al. Virtual histology intravascular ultrasound analysis of non-culprit attenuated plaques detected by grayscale intravascular ultrasound in patients with acute coronary syndromes. Am J Cardiol. 2010;105:48–53
  16. Choi SH, Chae A, Miller E, Messig M, Ntanios F, DeMaria AN, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol. 2008;52:24–32
  17. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316
  18. Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome (PCI-PROVE IT: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) substudy). J Am Coll Cardiol. 2009;54:2290–2295
  19. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54:293–302
  20. Qian J, Maehara A, Mintz GS, Margolis MP, Biro S, Stone GW, et al. Relation between individual plaque components and overall plaque burden in the prospective, multicenter virtual histology intravascular ultrasound registry. Am J Cardiol. 2009;104:501–506
  21. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004;110:1406–1412
  22. Ho PM, Fihn SD, Wang L, Bryson CL, Lowy E, Maynard C, et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J. 2007;154:846–851
  23. Bilodeau ML, Simon DI. Clopidogrel for the hot patient. Circ Cardiovasc Interv. 2009;2:495–496
  24. Tricoci P, Roe MT, Mulgund J, Newby LK, Smith SC, Pollack CV, et al. Clopidogrel to treat patients with non–ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006;166:806–811
  25. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622–1626
  26. Lewis BS, Mehta SR, Fox KA, Halon DA, Zhao F, Peters RJ, et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J. 2005;150:1177–1784
  27. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–972
  28. Movahed MR, John J, Hashemzadeh M, Jamal MM. Trends in the age adjusted mortality from acute ST segment elevation myocardial infarction in the United States (1988–2004) based on race, gender, infarct location and comorbidities. Am J Cardiol. 2009;104:1030–1034

 This work was supported by an unrestricted grant from SanofiAventis, Bridgewater, New Jersey; Blue Cross Blue Shield of Michigan, Detroit, Michigan; the Hewlett Foundation, Menlo Park, California; and the Mardigian Fund, Bloomfield, Michigan.

PII: S0002-9149(10)01723-6

doi: 10.1016/j.amjcard.2010.08.040

American Journal of Cardiology
Volume 107, Issue 1 , Pages 24-29 , January 2011

Article Tools

* Image Usage & Resolution